The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines

Languages

Service navigation

Search

Contact information

The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines

The aim of the Health Technology Assessment (HTA) is to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of ezetimibe-containing medicines compared to statins or fenofibrate in patients with hypercholesterolaemia or mixed/combined hyperlipidaemia.

Dokumente

HTA report (PDF, 10 MB, 04.06.2021)

Stakeholder feedback on the HTA report (PDF, 210 kB, 04.06.2021)

Scoping report (PDF, 1 MB, 14.07.2020)

Stakeholder feedback on the scoping report (PDF, 353 kB, 14.07.2020)

< back to HTA projects

Last modification 04.06.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/ezetimib.html